tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Crispr Therapeutics price target raised to $12 from $10 at Barclays

Barclays raised the firm’s price target on Crispr Therapeutics (CRSP) to $12 from $10 and keeps an Overweight rating on the shares post the Q2 report. The company beat estimates on better margins and double-digit Components and Systems growth, the analyst tells investors in a research note. The firm says market adoption of Crispr’s new products has been positive.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1